Rapid and safe development of antifibrotic drugs
Histology of a human heart slice with more than 40 percent fibrotic area; collagen accumulations as a sign of fibrosis are colored red.
Credit: Jan Weusthoff / Fraunhofer ITEM
Fraunhofer project FibroPaths®:
More than 100 million individuals worldwide suffer from organ fibrosis, a pathological proliferation of connective tissue in an organ, such as the lung, heart and liver. Hardly any causal treatments are available to date. The unmet medical need is partly due to the fact that the existing disease models for fibrosis research are insufficient and little predictive. Coordinated by the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, four Fraunhofer institutes have joined forces in the FibroPaths® project aimed at enabling rapid and safe development of antifibrotic drugs.
Organ fibroses are progressive diseases caused by a variety of triggers, including infection, autoimmune diseases, ischemia, exposure to toxic substances, and profibrotic metabolic conditions. They develop over a long period of time. As a result, the transferability and extrapolation of nonclinical data to humans poses a problem: The available in-vitro and ex-vivo methods do not provide a sufficient time frame for studying fibrosis and the results obtained in animal models are difficult to translate to the fibrotic processes actually taking place in humans. Moreover, a combination of imaging, molecular, and functional parameters to characterize organ fibrosis has not yet been established.
FibroPaths® is taking on these challenges. To this end, the institutes Fraunhofer ITEM, Fraunhofer IWS, Fraunhofer MEVIS and Fraunhofer IMW have teamed up. Their aim is to develop a novel system for preclinical testing of antifibrotic candidate drugs. It will be based on a standardized and automated biochip that includes human tissue and is thus closer to the real situation in humans. In addition, it will help avoid animal experiments in the sense of the 3Rs principle (replace, reduce, refine animal testing). The aim is that the innovative biochip will allow extensive structural, molecular and functional characterization of fibrotic processes. Furthermore, the project will include comprehensive functional and molecular data analyses using AI-assisted methods, and the establishment of a corresponding database.
With the FibroPaths® project, receiving Fraunhofer-internal funding until mid-2025, the Fraunhofer-Gesellschaft wants to help ensure that promising antifibrotic drug candidates are identified at a very early stage of development and taking into account the 3R principles, i.e. not as late as during or after the first clinical trials and thus at a late and expensive development phase.
Wissenschaftliche Ansprechpartner:
Prof. Dr. Dr. Thomas Thum
Fraunhofer ITEM Director and FibroPaths® Project Leader
thomas.thum@item.fraunhofer.de
Weitere Informationen:
https://www.item.fraunhofer.de/en/r-d-expertise/cardiopulmonary-research/project… To the FibroPaths® website
https://www.item.fraunhofer.de/en/press-and-media/press-releases/project-fibropa… To the press realease
Media Contact
All latest news from the category: Life Sciences and Chemistry
Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.
Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.
Newest articles
Organic matter on Mars was formed from atmospheric formaldehyde
Although Mars is currently a cold, dry planet, geological evidence suggests that liquid water existed there around 3 to 4 billion years ago. Where there is water, there is usually…
Engineers 3D print sturdy glass bricks for building structures
The interlocking bricks, which can be repurposed many times over, can withstand similar pressures as their concrete counterparts. What if construction materials could be put together and taken apart as…
New organic thermoelectric device
… that can harvest energy at room temperature. Researchers have succeeded in developing a framework for organic thermoelectric power generation from ambient temperature and without a temperature gradient. Researchers have…
